Give the Gift of Hope this Holiday Season! Support PWSA | USA's 2025 Angel Drive. Donate Now

Category: Blog

Ask Nurse Lynn: PWS and Aging

Question: Female, 65 years old, Deletion subtype My sister lives with caregivers in Alberta. She turned 65 this year, and over the last few years she has developed a number of health issues. Due to balance issues, she has been using a walker for the last couple of years. It is hard to find any...

You’re Invited: Webinar on Prader-Willi Syndrome and VYKAT™ XR (diazoxide choline)

Note: This event is hosted by Soleno Therapeutics and shared by PWSA | USA as an educational opportunity for the Prader-Willi syndrome (PWS) community. Families, caregivers, and professionals are invited to join Soleno Therapeutics for an upcoming educational webinar discussing Prader-Willi syndrome and VYKAT™ XR (diazoxide choline), a treatment for individuals 4 years and older...

Soleno Therapeutics to Invest $5 Million in Research Toward a Potential Cure for Prader-Willi Syndrome

PWSA | USA is excited to celebrate a powerful new commitment from Soleno Therapeutics, a company already making history in the Prader-Willi syndrome (PWS) community. Following the FDA approval of VYKAT™ XR (diazoxide choline extended-release tablets), the first-ever treatment for hyperphagia in PWS, Soleno has announced plans to invest up to $5 million in grant...

Calling Indiana PWS Families!

The Indiana Medicaid Drug Utilization Review (DUR) Board Meeting will be meeting October 17, 2025, starting at 10:00 AM EST. Here’s how you can help: The Indiana Medicaid DUR Board needs to hear directly from you – the parents, caregivers, and family members who understand the real-life impact of hyperphagia (excessive hunger) in PWS. One...

HERO Clinical Trial for ARD-101 Now Enrolling Open-Label Extension (OLE)

Earlier this year, Aardvark Therapeutics launched HERO, a global Phase 3 clinical trial investigating ARD-101, an innovative, orally administered treatment designed to help reduce hyperphagia (excessive hunger) and food-seeking behaviors in individuals with Prader-Willi syndrome (PWS). All patients who have completed treatment on the AVK-101-301 study through Week 12/End of Treatment will have the option to join...

Scroll to top